Copanlisib
- Generic Name
- Copanlisib
- Brand Names
- Aliqopa
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28N8O4
- CAS Number
- 1032568-63-0
- Unique Ingredient Identifier
- WI6V529FZ9
- Background
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was gr...
- Indication
Copanlisib is indicated for the treatment of adults with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. This indication was granted under accelerated approval; thus, continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Associated Conditions
- Relapsed Follicular Lymphoma
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.